Preoperative Single-dose Methylprednisolone Prevents Surgical Site Infections After Major Liver Resection: A Randomized Controlled Trial
- PMID: 33351452
- DOI: 10.1097/SLA.0000000000004720
Preoperative Single-dose Methylprednisolone Prevents Surgical Site Infections After Major Liver Resection: A Randomized Controlled Trial
Abstract
Objective: The primary aim of this study was to evaluate the efficacy of a single preoperative dose of methylprednisolone for preventing postoperative complications after major liver resections.
Summary background data: Hepatic resections are associated with a significant acute systemic inflammatory response. This effect subsequently correlates with postoperative morbidity, mortality, and length of recovery. Multiple small trials have proposed that the administration of glucocorticoids may modulate this effect.
Methods: This study was a parallel, dual-arm, double-blind randomized controlled trial. Adult patients undergoing elective major hepatic resection (≥3 segments) at a quaternary care institution were included (2013-2019). Patients were randomly assigned to receive a single preoperative 500 mg dose of methylprednisolone versus placebo. The main outcome measure was postoperative complications after liver resection, within 90 days of the index operation. Standard statistical methodology was employed (P < 0.05 = significant).
Results: A total of 151 patients who underwent a major hepatic resection were randomized (mean age = 62.8 years; 57% male; body-mass-index = 27.9). No significant differences were identified between the intervention and control groups (age, sex, body-mass-index, preoperative comorbidities, hepatic function, ASA class, portal vein embolization rate) (P > 0.05). Underlying hepatic diagnoses included colorectal liver metastases (69%), hepatocellular carcinoma (18%), noncolorectal liver metastases (7%), and intrahepatic cholangiocarcinoma (6%). There was a significant reduction in the overall incidence of postoperative complications in the methylprednisolone group (31.2% vs 47.3%; P = 0.042). Patients in the glucocorticoid group also displayed less frequent organ space surgical site infections (6.5% vs 17.6%; P = 0.036), as well as a shorter length of hospital stay (8.9 vs 12.5 days; P = 0.015). Postoperative serum bilirubin and prothrombin timeinternational normalized ratio (PT-INR) levels were also lower in the steroid group (P = 0.03 and 0.04, respectively). Multivariate analysis did not identify any additional significant modifying factor relationships (estimated blood loss, duration of surgery, hepatic vascular occlusion (rate or duration), portal vein embolization, drain use, etc) (P > 0.05).
Conclusions: A single preoperative dose of methylprednisolone significantly reduces the length of hospital stay, postoperative serum bilirubin, and PT-INR, as well as infectious and overall complications following major hepatectomy.
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
Conflict of interest statement
The authors report no conflicts of interest.
Comment in
-
Response to the Comment on "Preoperative single-dose Methylprednisolone Prevents Surgical Infections After Major Liver Resection: A randomized controlled trial".Ann Surg. 2021 Dec 1;274(6):e907. doi: 10.1097/SLA.0000000000004919. Ann Surg. 2021. PMID: 33938489 No abstract available.
-
Comment on"Preoperative Single-dose Methylprednisolone Prevents Surgical Site Infections After Major Liver Resection: A Randomized Controlled Trial": Preoperative Single-dose Methylprednisolone Prevents Surgical Site Infections or Protects the Hepatic Function.Ann Surg. 2021 Dec 1;274(6):e906-e907. doi: 10.1097/SLA.0000000000004926. Ann Surg. 2021. PMID: 33938496 No abstract available.
-
[Preoperative administration of methylprednisolone leads to fewer complications after major liver resection].Chirurg. 2022 Apr;93(4):399-400. doi: 10.1007/s00104-022-01620-z. Epub 2022 Mar 4. Chirurg. 2022. PMID: 35244735 German. No abstract available.
References
-
- Faist E, Schinkel C, Zimmer S. Updates on the mechanisms of immune suppression of injury and immune modulation. World J Surg 1996; 20:454–459.
-
- Robertson CM, Coopersmith CM. The systemic inflammatory response syndrome. Microbes Infect 2006; 8:1382–1389.
-
- Hill AG. Initiators and propagators of the metabolic response to injury. World J Surg 2000; 24:624–629.
-
- Biffl WL, Moore EE, Moore FA, et al. Interleukin-6 in the injured patient. Marker of injury or mediator of inflammation? Ann Surg 1996; 224:647–664.
-
- Wiezer MJ, Meijer C, Vuylsteke R, et al. Is major liver surgery associated with an increased systemic inflammatory response? A prospective comparison of hemihepatectomy and other major abdominal surgery. Liver 1999; 19:220–227.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
